Drug Trial Radar · NCT07484217
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
508
Planned (sponsor's estimate)
Start
Feb 23, 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Axsome Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.
Conditions
- Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions
Solriamfetol 150 MGDrug
Solriamfetol tablets, taken once daily
PlaceboDrug
Placebo tablets, taken once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from randomization to relapse of depressive symptomsTime frame: Up to 24 weeks.
Locations
40 sites in 1 country. Site status is shown where the registry gives one.
Clinical Research Site
Tucson, Arizona · Recruiting
Clinical Research Site
Bellflower, California · Recruiting
Clinical Research Site
Chino, California · Recruiting
Clinical Research Site
Glendale, California · Recruiting
Clinical Research Site
Imperial, California · Recruiting
Clinical Research Site
Los Angeles, California · Recruiting
Clinical Research Site
Oceanside, California · Recruiting
Clinical Research Site
Redlands, California · Recruiting
Clinical Research Site
San Diego, California · Recruiting
Clinical Research Site
Sherman Oaks, California · Recruiting
Clinical Research Site
Walnut Creek, California · Recruiting
Clinical Research Site
Jacksonville, Florida · Recruiting
Clinical Research Site
Miami, Florida · Recruiting
Clinical Research Site
Miami, Florida · Recruiting
Clinical Research Site
Atlanta, Georgia · Recruiting
Clinical Research Site
Norcross, Georgia · Recruiting
Clinical Research Site
Snellville, Georgia · Recruiting
Clinical Research Site
Chicago, Illinois · Recruiting
Clinical Research Site
Pikesville, Maryland · Recruiting
Clinical Research Site
Springfield, Massachusetts · Recruiting
Clinical Research Site
Las Vegas, Nevada · Recruiting
Clinical Research Site
Las Vegas, Nevada · Recruiting
Clinical Research Site
Cherry Hill, New Jersey · Recruiting
Clinical Research Site
Toms River, New Jersey · Recruiting
Clinical Research Site
Brooklyn, New York · Recruiting
Clinical Research Site
New York, New York · Recruiting
Clinical Research Site
New York, New York · Recruiting
Clinical Research Site
Staten Island, New York · Recruiting
Clinical Research Site
The Bronx, New York · Recruiting
Clinical Research Site
Cincinnati, Ohio · Recruiting
Clinical Research Site
Cincinnati, Ohio · Recruiting
Clinical Research Site
Edmond, Oklahoma · Recruiting
Clinical Research Site
Oklahoma City, Oklahoma · Recruiting
Clinical Research Site
Portland, Oregon · Recruiting
Clinical Research Site
Memphis, Tennessee · Recruiting
Clinical Research Site
Austin, Texas · Recruiting
Clinical Research Site
Bellaire, Texas · Recruiting
Clinical Research Site
Dallas, Texas · Recruiting
Clinical Research Site
Houston, Texas · Recruiting
Clinical Research Site
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.